N ORTHWEST A IDS E DUCATION AND T RAINING C ENTER CROI 2015: Hot Topics in HIV Primary Care Brian R. Wood, MD Assistant Professor of Medicine, University.

Slides:

Advertisements

Similar presentations

Washington D.C., USA, July 2012www.aids2012.org Access to HCV treatment for people with HIV/HCV Professor Gregory Dore Viral Hepatitis Clinical Research.

Advertisements

Stents Are Not Enough: Statins Keith Channon Department of Cardiovascular Medicine University of Oxford John Radcliffe Hospital, Oxford.

Goldstraw et al. J Thorac Oncol 2007 Why should we want to screen? Survival (years)

A5336 A Phase IIa, Double-blind, Placebo-controlled, Randomized Trial of Ruxolitinib in Antiretroviral-treated HIV-Infected Adults CAB Draft Discussion.

Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2013.

Chronic diseases in HIV Francois Venter Wits Reproductive Health & HIV Institute

Epidemiological evidence for a protective role for statins in Community Acquired Pneumonia British Thoracic Society Winter Meeting 2012, London Yana Vinogradova.

Is low-dose Aspirin use associated with a reduced risk of colorectal cancer ? a QResearch primary care database analysis Prof Richard Logan, Dr Yana Vinogradova,

Washington D.C., USA, July 2012www.aids2012.org Stroke in Human Immunodeficiency Virus (HIV) infected patients M. Nigo, A. Walker, D. Lucido, A.

N ORTHWEST A IDS E DUCATION AND T RAINING C ENTER CROI 2015: Treatment and Cure Highlights Shireesha Dhanireddy Robert Harrington March 17, 2014 No financial.

N ORTHWEST AIDS E DUCATION AND T RAINING C ENTER CROI 2015: What’s New in Hepatitis? Nina Kim, MD Associate Professor of Medicine Division of Allergy &

HIV Disease in Older Patients Donna M. Gallagher, ANP The International AIDS Society–USA DM Gallagher, ANP. Presented at IAS–USA/RWCA Clinical Conference,

Role of Antiretroviral Therapy, Viral Replication, and HIV Infection in Atherosclerosis Priscilla Y. Hsue, Peter W. Hunt, Jeffrey N. Martin, Amanda Schnell,

N ORTHWEST A IDS E DUCATION AND T RAINING C ENTER 2014 IAS-USA Treatment Guidelines Brian R. Wood, MD Medical Director, NW AETC ECHO Assistant Professor.

Cardiovascular Disease: Predicting Risk and Monitoring Outcomes Monica R. Shah, MD, FACC NHLBI AIDS Coordinator Conference on Retroviruses and Opportunistic.

NCD Complications in HIV Patients Esteban Martinez Hospital Clínic University of Barcelona Barcelona SPAIN Washington D.C., USA,

N ORTHWEST A IDS E DUCATION AND T RAINING C ENTER HIV and Non Hodgkin Lymphoma Virginia C. Broudy, MD September 25, 2014 Presentation prepared by: Presenter.

Unit 5: IPT Isoniazid TB Preventive Therapy

Introduction DCDOH supports HIV test and treat activities - increased number of HIV tests performed, emphasis on earlier linkage to care. Limited data.

THE LIPID PANEL What are we missing? Robert St. Amant, MD, FAAFP Diplomate, American Board of Clinical Lipidology Baton Rouge General Medical Director,

HYPERLIPIDAEMIA. 4S 4444 patients –Hx angina or MI –Cholesterol Simvastatin 20mg (10-40) vs. placebo FU 5 years  total cholesterol 25%;  LDL.

Title: Presenters: Date: Proportion of Newly Diagnosed Non-Small Cell Lung Cancer Patients That Would Have Been Eligible for Lung Cancer Screening Division.

Abstract Results Objectives Results Conclusions Background Methods V-1637 Background-At the CORE center in Chicago, despite an on-site hepatitis clinic.

Finding N.E.M.O. Marvin R. Balaan, MD, FCCP System Division Director, Division of Pulmonary and Critical Care Medicine Allegheny Health Network, Pittsburgh.

N ORTHWEST AIDS E DUCATION AND T RAINING C ENTER PrEP 201: Beyond the Basics Joanne Stekler, MD MPH Associate Professor of Medicine University of Washington.

Prevention and Early Detection of Breast Cancer: Weighing the Risks and Benefits Kathy J. Helzlsouer, M.D., M.H.S. Prevention and Research Center, Women’s.

HIV Organ Policy Equity (HOPE) Act Research Criteria: follow-up discussion Advisory Committee on Organ Transplantation April 13, 2015.

Fatal and Non-fatal Hepatic Failure in HIV-infected versus HIV-uninfected Persons Enrolled in Kaiser Permanente California (KP), a Large Managed Care Organization.

Nguyen ML, Sumbry A, Reddy D, Harvey K, Gunthel C, Wang W, Tsui C, Ziemer D, del Rio C, Young JL Increased Incidence of Non AIDS-related Malignancies and.

Translational Science in Cancer Health Disparities Research Peter Ujhazy, M.D., Ph.D. Program Director Translational Research Program Division of Cancer.

Early Detection of Lung Cancer & Beyond

1 Journal Club Alcohol, Other Drugs, and Health: Current Evidence March–April 2012.

I. Jean Davis, PhD, PA, AAHIVS Manager - Clinical Services Desert AIDS Project.

David Dowdy, Elvin Geng, Katerina Christopoulos, James Kahn, C. Bradley Hare, Daniel Wlodarczyk, Diane Havlir Internal Medicine Residency Program, UCSF.

WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.

Predictive Value of Coronary Calcium Scoring Matthew Budoff, MD, FACC, FAHA Associate Professor of Medicine UCLA School of Medicine Director, Cardiac CT.

HIV and STI Department, Health Protection Agency - Colindale HIV and AIDS Reporting System The threshold for an ART secondary prevention effect on HIV.

Potential Utility of Tipranavir in Current Clinical Practice Daniel R. Kuritzkes, MD Director of AIDS Research Brigham and Woman’s Hospital Division of.

The SHAPE Trial Advisory Meeting – Part II GoToMeeting Session Monday Nov 9 th, 12PM EST Dial +1 (312)

Clinical Trial Results. org METEOR Trial Presented at the American College of Cardiology Annual Scientific Session March, 2007 Presented by Dr. John R.

This presentation is intended for educational use only, and does not in any way constitute medical consultation or advice related to any specific patient.

N ORTHWEST A IDS E DUCATION AND T RAINING C ENTER Major Changes to the HHS Adult and Adolescent HIV Treatment Guidelines: April 2015 Brian R. Wood, MD.

Isolated Hepatitis B Core Antibody

Figure 2: Trends in currently prescribed antiretroviral therapy % prescribed HAART increased from 74% to 83% Trends in ART use, HIV viral load, and CD4.

Importance of HIV Education of HIV Screening and Risk Among Adults 65 Years Old and Older In A Senior Center JESSICA WARD RN,BSN,FNP COPPIN STATE UNIVERSITY.

REDUCED LUNG-CANCER MORTALITY WITH LOW-DOSE COMPUTED TOMOGRAPHIC SCREENING The National Lung Screening Trial Research Team N Engl J Med 2011;365:

Decoding the USPSTF By: Dr Vikram Arora Heritage Valley Health System.

Weekly Alendronate Safe and Effective at Increasing Bone Mineral Density in HIV-Infected Persons on Antiretroviral Therapy Slideset on: McComsey GA, Kendall.

A Survival Comparison between HIV+ U.S.-born Latinos and Foreign-born Latinos in Houston, Texas Raouf Arafat, MD, MPH, Adebowale Awosika- Olumo.

Slideset on: Patel P, Hanson DL, Sullivan PS, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the.

Date of download: 6/3/2016 From: U.S. Trends in Antiretroviral Therapy Use, HIV RNA Plasma Viral Loads, and CD4 T-Lymphocyte Cell Counts Among HIV-Infected.

The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.

CHEST 2014; 145(4): 호흡기내과 R3 박세정. Cigarette smoking ㅡ the most important risk factor for COPD in the US. low value of FEV 1 : an independent predictor.

Problems of HIV Infection in the HAART Era Akihiko Suganuma M.D. Tokyo Metropolitan Komagome Hospital Department of Infectious Diseases.

Previous SVR With Interferon-Based Therapy for HCV Lowers Risk of Hepatotoxicity in HIV/HCV-Coinfected Individuals on Antiretroviral Therapy Slideset on:

Statins Reduce the Risk of Lung Cancer in Humans CHEST 2007; 131:1282–1288 R4 Byunghyuk Yang.

Henry Masur, MD Bethesda, Maryland

Statins The AURORA Trial Reference Fellstrom BC. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360. A.

How Do We Individualize Guidelines in an Era of Personalized Medicine? Douglas K. Owens, MD, MS VA Palo Alto Health Care System Stanford University, Stanford.

Dolutegravir plus Rilpivirine as Maintenance Dual Therapy SWORD-1 and SWORD- 2: Design

VACS Cancer Core Robert Dubrow, PhD, MD Founding Director

Risk factors for cervical intraepithelial neoplasia recurrence after loop electrosurgical excision procedure in HIV-1-infected and non-infected women.

Overview. 5 Things You Need to Know About Statin Selection in Patients With HIV Infection.

100 Partners PrEP[5] Efficacy 75% Adherence 81% 80

Cholesterol Management in HIV-infected and Uninfected Patients: The Veterans Aging Cohort Study Leaf, DA, Goulet J, Goetz MB, Oursler KA, Gilbert C, Frieberg.

Impact of Hepatitis C, HIV, or Both on Survival in Veterans in Care Before and After the Introduction of HAART (1996) SL Fultz, MD, MPH CH Chang, PhD AA.

Reconciling Aging With HIV

The following slides highlight a report on a presentation at the American College of Cardiology 2004, Scientific Sessions, in New Orleans, Louisiana on.

Simvastatin in Patients With Prior Cerebrovascular Disease: HPS

Khai Hoan Tram, Jane O’Halloran, Rachel Presti, Jeffrey Atkinson

Presentation transcript:

N ORTHWEST A IDS E DUCATION AND T RAINING C ENTER CROI 2015: Hot Topics in HIV Primary Care Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical Director, NW AETC ECHO March 5, 2015

ECHO CROI Reviews /5/153/12/153/19/15 Brian Wood: Primary Care Shireesha Dhanireddy: New Treatments Nina Kim: HCV Coinfection Ruanne Barnabas: Prevention Issues

CROI 2015: Primary Care Topics Cancer risk and lung cancer screening Benefits of statins beyond cholesterol reduction

“Cancers in Young and Old and Lung Cancer in HIV” CROI 2015

Cancer Risk in HIV+ Over 65 Years Old Case-cohort study 5% Medicare registry sample All cancers in people over 65 in large cancer registry Association between HIV and cancer incidence Adjusted for age, race, sex, calendar year Yanik El et al. Abstract 725.

Cancer Risk in HIV+ Over 65 Years Old 5-year cumulative incidence (%)

CD4 Count as a Predictor of Lung Cancer Risk and Prognosis 26,065 HIV+ in VACS Incident non-small cell lung cancer cases Cox regression models for lung cancer risk, CD4 count Adjusted for: age, sex, race, smoking, h/o pneumonia or COPD Compared survival based on HIV status, CD4 +/- 200 Sigel K et al. Abstract 728.

Smoking Outweighs HIV-Related Risk Factors for Non-AIDS-Defining Cancers Adults in NA-ACCORD Non-AIDS-defining cancers HIV-related risk factors and smoking ≈40K adults, ≈160K person-years Most common cancers: lung (17%), anal (16%), prostate (10%), 9% HL, 7% liver, 7% breast Source. Althoff KN et al. Abstract 726. Population attributable risk (PAF), % Including lung cancer Excluding lung cancer

US Preventive Services Task Force (USPSTF) Lung Cancer Screening Recs Ann Intern Med. 2014;160:

Lung Cancer Screening in HIV+ Smokers 14 French clinical centers; single low-dose chest CT Inclusion: age >40, ever smoked in last 3 years, >20 pack- years, CD4 nadir subjects: -Median age: 49.8, nadir CD4: 168, last CD4: % with last viral load <50 -Median smoking pack-years: subjects (21%) had a significant finding 18 diagnostic procedures in 15 subjects Makinson et al. Abstract 727.

Conclusions: Screening is safe and effective; USPSTF guidelines may miss early CA Questions: When to start screening? Which criteria- Age? Pack-years? CD4 nadir? Lung Cancer Screening in HIV+ Smokers

Benefits of Statins Beyond Cholesterol Reduction CROI 2015

1) Overton ET et al. CID, May ) Galli L et al. AIDS, Oct 2014.

Statin Reduces Non-Calcified Coronary Plaque Burden Double-blind, placebo-controlled, single-center, RCT Atorvasatatin vs. placebo 40 subjects, no known CAD, LDL , subclinical atherosclerosis (plaques) on CTA, stable on ART After 12 months, atorvastatin reduced non-calcified coronary plaque volume (-19.4% vs %, p = 0.009) Reduced overall plaque volume, # of high-risk plaques, Lp-PLA 2 80% progression with placebo vs. 35% with atorvastatin Lo J et al. Abstract 136.

More Potential Statin Benefits Rosuvastatin arrests progression of carotid intima media thickness (Longenecker CT et al. Abstract 137) Simvastatin protects human aortic endothelial cells from oxidative damage (Panigrahi S et al. Abstract 298LB) Atorvastatin partially reverses the HIV-mediated reduction of heme oxygenase (HO-1) in macrophages and may have benefit in HAND (Duncan MR et al. Abstract 502) Statins improve SVR and reduce fibrosis progression and HCC among HCV+ persons (Butt AA et al. Abstract 643) Statins have initial benefit for BMD over placebo but benefit doesn’t persist at 96 weeks and has detrimental effects on insulin resistance (Erlandson KE et al. Abstract 771)

Weigh benefits against risks: hepatotoxicity, myopathy, drug interactions, polypharmacy, cost Justice A et al. Lancet HIV, January 2015.

Conclusions HIV infection raises risk of non-AIDS-defining malignancies, though smoking outweighs HIV-related risk factors Lung cancer screening should be considered for those at high risk, but need to define best criteria for HIV+ Statins have many potential benefits, including reduced progression of subclinical high-risk coronary plaques We need better guidelines for assessing CAD risk and statin initiation for HIV+ persons (A5332; reprievetrial.org)